H.C. Wainwright Starts Tvardi Therapeutics Inc (TVRD) at Buy Jun 8, 2026 06:39AM
Tvardi Therapeutics (TVRD) Misses Q1 EPS by 73c May 8, 2026 08:22AM
Tvardi Therapeutics (TVRD) files $200M mixed shelf May 1, 2026 04:08PM
Barclays Downgrades Tvardi Therapeutics Inc (TVRD) to Underweight Apr 20, 2026 04:07AM
Tvardi Therapeutics (TVRD) Reiterated at Neutral by Cantor Fitzgerald After Q4 Results Apr 1, 2026 07:08AM


Apr 1, 2026 06:59AM Tvardi Therapeutics Inc (TVRD) PT Lowered to $3 at Piper Sandler
Mar 31, 2026 05:00PM Tvardi Therapeutics (TVRD) Misses Q4 EPS by 78c
Feb 4, 2026 06:09AM Lucid Capital Markets Upgrades Tvardi Therapeutics Inc (TVRD) to Buy
Nov 13, 2025 06:19PM Tvardi Therapeutics (TVRD) Misses Q3 EPS by 59c
Oct 14, 2025 06:35AM Raymond James Downgrades Tvardi Therapeutics Inc (TVRD) to Market Perform
Oct 13, 2025 04:07PM Barclays Downgrades Tvardi Therapeutics Inc (TVRD) to Equalweight
Oct 13, 2025 12:13PM Tvardi Therapeutics Inc (TVRD) PT Lowered to $15 at BTIG
Oct 13, 2025 12:12PM Tvardi Therapeutics Inc (TVRD) PT Lowered to $10 at Oppenheimer
Oct 13, 2025 10:12AM Cantor Fitzgerald Downgrades Tvardi Therapeutics Inc (TVRD) to Neutral
Oct 13, 2025 09:59AM Piper Sandler Downgrades Tvardi Therapeutics Inc (TVRD) to Neutral
Oct 13, 2025 05:31AM Barclays Starts Tvardi Therapeutics Inc (TVRD) at Overweight
Jul 14, 2025 06:24AM Raymond James Starts Tvardi Therapeutics Inc (TVRD) at Outperform
Jul 11, 2025 06:46AM Cantor Fitzgerald Starts Tvardi Therapeutics Inc (TVRD) at Overweight
Jun 12, 2025 03:52AM Piper Sandler Starts Tvardi Therapeutics Inc (TVRD) at Overweight
May 30, 2025 04:07PM Tvardi Therapeutics (TVRD) Files for 2.08M Share Offering by Selling Stockholders
May 28, 2025 05:09AM BTIG Reiterates Buy Rating on Tvardi Therapeutics Inc (TVRD)
May 21, 2025 06:02AM Oppenheimer Starts Tvardi Therapeutics Inc (TVRD) at Outperform, PT $65
May 15, 2025 06:05AM BTIG Starts Tvardi Therapeutics Inc (TVRD) at Buy
Apr 30, 2025 07:11AM Lucid Capital Markets Starts Tvardi Therapeutics Inc (TVRD) at Buy